FIORINAL
LOE ApproachingNDAORALTABLET
Approved
May 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FIORINAL is an oral tablet combination analgesic approved in 1976 for pain management. The product contains a fixed-dose combination of active ingredients designed for symptomatic relief. It represents a legacy small-molecule therapeutic in the pain management category.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure; expect brand team focus on retention and lifecycle management strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's mature, non-growth stage under AbbVie ownership. Working on FIORINAL offers limited career acceleration; opportunities center on cost optimization, generic transition planning, and defensive market strategies rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on FIORINAL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.